title: Experimental approaches for the treatment of malignant gliomas.
abstract: Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most common primary tumors of the brain. Over the past 30 years, the standard treatment for these tumors has evolved to include maximal safe surgical resection, radiation therapy and temozolomide chemotherapy. While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients. There has, however, been recent substantial progress in our mechanistic understanding of tumor development and growth. The translation of these genetic, epigenetic and biochemical findings into therapies that have been tested in clinical trials is the subject of this review.
authors.affiliation: Surgical and Molecular Neuro-oncology Unit, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
authors.forename: Leopold
authors.initials: L
authors.lastname: Arko
authors.forename: Igor
authors.initials: I
authors.lastname: Katsyv
authors.forename: Grace E
authors.initials: GE
authors.lastname: Park
authors.forename: William Patrick
authors.initials: WP
authors.lastname: Luan
authors.forename: John K
authors.initials: JK
authors.lastname: Park
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001691:Biological Therapy; D002986:Clinical Trials as Topic; D018450:Disease Progression; D057890:Epigenomics; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors